Completed PHASE4 INTERVENTIONAL NCT00425126

Effect of Procrit (Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation

Effect of Procrit(Epoetin Alfa) on Preventing Delayed Graft Function After Deceased Donor Renal Transplantation

Sponsor: West Penn Allegheny Health System

Updated 6 times since 2017 Last updated: May 25, 2010 Started: Feb 28, 2007 Primary completion: Feb 28, 2010 Completion: Feb 28, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00425126, this PHASE4 trial focuses on Delayed Graft Function and remains completed. Sponsored by West Penn Allegheny Health System, it has been updated 6 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE4
Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Feb 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

West Penn Allegheny Health System

Data source: West Penn Allegheny Health System

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pittsburgh, United States